Week Ending August 8, 2022

Combinations, Ex Vivo Manipulation May Be Key to Enhancing T-Cell Activity in Lung Cancer
“Investigational approaches aimed at transforming the tumor microenvironment for patients with lung cancer are going to be especially important as immunotherapy moves into the curative setting, explained Roy S. Herbst, MD, PhD.”

Biagio Ricciuti, MD, Looks Toward Future Research in NSCLC Involving PD-L1 Expression
“At the 2022 American Society of Clinical Oncology Annual Meeting, CancerNetwork® spoke with Biagio Ricciuti, MD, of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute, about future research into efficacy of pembrolizumab (Keytruda) monotherapy in patients with non–small cell lung cancer (NSCLC) who have PD-L1 tumor proportion scores (TPS) of 90% or more.”

New Screening Recommendations Not Likely to Erase Lung Cancer Disparities
“A new analysis suggests that efforts to reduce lung cancer disparities by expanding screening eligibility are unlikely to erase gaps in outcomes.”

What Is Stage 2 Lung Cancer?
“When doctors diagnose lung cancer, they also try to determine what stage the cancer is at. This helps them decide on the best course of treatment. The most prevalent type of lung cancer, non-small cell lung cancer, has four stages. Stage 2 indicates the cancer may have spread beyond the lung into nearby lymph nodes.”

Lung Cancer Remains the Leading Cause of Cancer Deaths in the U.S.
“Emily Daniels, who lives with her husband and their young son in Golden, CO, was 32 years old, and in the 33rd week of her pregnancy, she began feeling tightness in her chest. She wisely had it checked out, and a CT scan found two blood clots in her lungs. The scan also discovered a mass, which a biopsy confirmed was stage IV lung cancer.”

Survey Reveals That Most Americans Are Not Concerned About Getting Lung Cancer
“A recent survey shows that only 40% of Americans are concerned that they might get lung cancer, and only about one in five have talked to their doctor about their risk for the disease, despite lung cancer being the leading cause of cancer deaths in the United States.”

Lung Cancer Genes Found in Large-Scale Genomic Study
“New links between genes and lung cancer have been uncovered by a team at Baylor College of Medicine. The largest genome-wide association study to date in a diverse population, it revealed five new susceptibility genes and 10 new variant associations from known risk genes. The team also further validated another 24 associations in different populations.”

4 Exercises That Are A Must For Lung Cancer Patients To Breathe Easy
“Lung cancer just like other cancers develops at the cellular levels. It originates in the lining of air passages and in the tissues. the abnormal cells keep multiplying and eventually grows out of control. that is when it start spreading to the lungs.”

HER3 Emerges as Intriguing Treatment Target in Lung Cancer
“Recent research has thrust HER3 into the spotlight as a potentially effective therapeutic target for patients with lung cancer for whom limited treatment options exist. HER3 is overexpressed in upward of 40% of patients with lung cancer, including approximately 83% of patients with non–small cell lung cancer (NSCLC), and is associated with poor clinical outcomes.”

Advanced Lung Cancer: Therapy for Fatigue, Depression, and Quality of Life
“In patients with advanced lung cancer, Acceptance and Commitment Therapy (ACT) – a mindfulness-based behavioral therapy — significantly improved depression, anxiety, fatigue, and quality of life, and showed a high rate of patient retention. These were among clinical trial findings published in the Asia-Pacific Journal of Oncology Nursing.”

This Is the No. 1 Lung Cancer Symptom People Ignore, Doctors Say
“Lung cancer is the second most common form of cancer in both men and women, with over 230,000 new cases diagnosed each year. Yet according to the American Cancer Society (ACS), it is “by far the leading cause of cancer death, making up almost 25 percent of all cancer deaths.”

What You Can Expect During Early Stage Lung Cancer
“Lung cancer is most responsive to treatment when detected in the early stages. The prognosis for stage 1 lung cancer is promising, with the five-year survival rate for stage 1 non-small cell lung cancers ranging between 76% and 92%. Many patients can expect to be cured of lung cancer if treated promptly.”

Misdiagnosed Lung Cancer and the Cost of Diagnosis Delays
“Lung cancer is the most commonly misdiagnosed cancer.1 When detected in an early stage, lung cancer is highly treatable. However, if lung cancer is not identified or misdiagnosed, it may progress to a more advanced stage and become more difficult to treat.”

Larotrectinib Demonstrates Favorable Long-Term Responses in NTRK Fusion–Positive Lung Cancer
“Larotrectinib (Vitrakvi) continued to elicit durable responses and a low toxicity profile in patients with NTRK fusion–positive lung cancer, according to long-term follow-up data from the phase 2 NAVIGATE trial (NCT02576431) and phase 1 LOXO-TRK-14001 trial (NCT02122913) presented at the IASLC 2022 World Conference on Lung Cancer.”

First-line Durvalumab Plus Tremelimumab Improves OS in Patients with Metastatic NSCLC
“The combination use of first-line durvalumab (Imfinzi) plus tremelimumab for the treatment of patients with metastatic non–small cell lung cancer (NSCLC) improved overall survival (OS) compared with standard-of-care chemotherapy, according to an exploratory analysis of the Chinese cohort in the phase 3 NEPTUNE study (NCT02542293) presented at the IASLC 2022 World Conference on Lung Cancer.”

Early diagnosis of lung cancer among younger vs. older adults: widening disparities in the era of lung cancer screening
“Younger patients with lung cancer are significantly more likely than older patients to be diagnosed with later stages of disease, illustrating the need to develop strategies to increase the early detection of lung cancer among younger patients who are currently ineligible for lung cancer screening.”

Addressing the Current Challenges in Lung Cancer Care